Journal Article

Niacin in HIV-Infected Individuals with Hyperlipidemia Receiving Potent Antiretroviral Therapy

Marisa T. Gerber, Kristin E. Mondy, Kevin E. Yarasheski, Henning Drechsler, Sherry Claxton, John Stoneman, Debra DeMarco, William G. Powderly and Pablo Tebas

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 39, issue 3, pages 419-425
Published in print August 2004 | ISSN: 1058-4838
Published online August 2004 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/422144
Niacin in HIV-Infected Individuals with Hyperlipidemia Receiving Potent Antiretroviral Therapy

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Background. Extended release (ER)—niacin therapy, which has been associated with reduced glucose tolerance in human immunodeficiency virus (HIV)—seronegative individuals, has not been evaluated in the HIV-infected population.

Journal Article.  4021 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.